New therapy trial from Australian researchers nearly doubles breast cancer cure rates
A phase 3 clinical trial from Melbourne’s Peter MacCallum Cancer Center has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved the cure rate for patients with the most common kind of breast cancer. In the present phase 3 trial, 510 patients were randomized to receive chemotherapy with either intravenous nivolumab or placebo. In patients treated with nivolumab plus chemotherapy, rates were statistically significant, nearly double those who received placebo plus chemo: 24.5% versus 13.8%, respectively.